top of page
METABOLIC PROFILING RESEARCH GROUP
News
It’s always an honor to have our work and research mentioned by the media and in the press. We are especially pleased when our work reaches readers outside the scientific community. Read on to see some of the latest stories about our findings.
A team of scientists from the National University of Singapore (NUS) has successfully identified the urinary biomarkers of an emerging subclass of synthetic cannabinoids, called OXIZID, to monitor potential abuse. OXIZIDs were the new synthetic cannabinoids identified in Singapore in 2021.
https://news.nus.edu.sg/biomarkers-to-detect-synthetic-cannabinoid-consumption/
https://news.nus.edu.sg/biomarkers-to-detect-synthetic-cannabinoid-consumption/
Ziteng Wang is the Drug Metabolism and Disposition Highlighted Trainee Author for the October 2022 issue. Dr. Wang is a postdoctoral fellow in the Department of Pharmacy at the National University of Singapore under the tutelage of Professor Eric Chun Yong Chan. The DMD article that earned his selection as a Highlighted Trainee Author is titled “Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib” and is available at https://doi.org/10.1124/dmd.122.000928.
The medicinal and recreational consumption of cannabis is increasingly becoming legalised in many countries across the world. Against this shift is the growing issue of “synthetic cannabis”, which is known to sneak past law enforcement and go undetected in drug tests. Some versions are found to have more potent side effects than naturally cultivated cannabis.
Lloyd Wei Tat Tang is the Journal of Pharmacology and Experimental Therapeutics Highlighted Trainee Author for the August 2022 issue. He is currently a fourth and final-year PhD candidate in the Department of Pharmacy at the National University of Singapore under the tutelage of Professor Eric Chan. The JPET article that earned his selection as a Highlighted Trainee Author is titled “Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban” and is available at https://doi.org/10.1124/jpet.122.001222.
Scientists from the National University of Singapore (NUS) Department of Pharmacy have developed an improved pharmaceutical drug for the treatment of the most common heart rhythm disturbance – atrial fibrillation (AF). The 8-member research team took 8 years to achieve this technological breakthrough which could benefit millions of AF patients worldwide.
July 2022
July 2022
A team of researchers from the National University of Singapore (NUS) has come up with a new solution to boost the surveillance of designer drug abuse. Led by Professor Eric Chan from the NUS Department of Pharmacy, the team has identified three new urinary biomarkers that could be used to detect consumption of ADB-BUTINACA, an emerging synthetic cannabinoid which is a type of new psychoactive substance (NPS). The innovative approach used to identify the biomarkers can be applied to other existing and new synthetic cannabinoids.
August 2021
August 2021
bottom of page